Milestone Pharmaceuticals Inc

NASDAQ MIST

Data sourced from

and

Download Data

Milestone Pharmaceuticals Inc Gross Working Capital 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -42.19%

Milestone Pharmaceuticals Inc Gross Working Capital 3 year CAGR is -42.19% for the Trailing 12 Months (TTM) ending March 31, 2024, a -236.07% change year over year. Gross working capital is a financial metric that represents the amount of a company's current assets available to cover its current liabilities and short-term debt obligations. It is calculated by subtracting the sum of current liabilities and short-term debt from the total current assets of a company. Gross working capital provides insights into a company's short-term liquidity and its ability to meet its financial obligations in the near future. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Milestone Pharmaceuticals Inc Gross Working Capital for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 327.20 M, a -31.48% change year over year.
Milestone Pharmaceuticals Inc Gross Working Capital for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 477.54 M, a 3.36% change year over year.
Milestone Pharmaceuticals Inc Gross Working Capital for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 462.02 M, a -5.57% change year over year.
Milestone Pharmaceuticals Inc Gross Working Capital for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 489.29 M, a 570.64% change year over year.

NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees	47
Sector	Healthcare
Industry	Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends